Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned… Read More
Gowling WLG (Canada) LLP is pleased to welcome 32 new professionals to its partnership, effective Jan. 1, 2024. Representing the firm’s seven offices across Canada, these professionals have continued to… Read More
Hospitalized patients are more complex than they used to be. That’s the finding of a new UBC faculty of medicine study in JAMA Internal Medicine which set out to measure something researchers… Read More
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11 th in San Francisco VANCOUVER, BC – PharmAla Biotech Holdings Inc…. Read More
Long term, multi-year supply agreement provides Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9’s targeted radiopharmaceutical programs for treatment of solid and liquid tumors…. Read More
